Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2026)

Lyell Immunopharma has reported Cash from Financing Activities for 7 years, with the latest figure at $51.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 5172100.0% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102.1 million (up 7755.92% YoY) and the FY2025 annual result came in at $50.4 million, up 3701.36% from the prior year.
• Cash from Financing Activities improved to $51.7 million in Q1 2026 per LYEL's latest filing, from $222000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $51.7 million in Q1 2026 and troughed at -$143000.0 in Q3 2023.
• A 5-year average of $7.2 million and a median of $810500.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 103.0% in 2023, then soared 5172100.0% in 2026.
• Over 5 years, Cash from Financing Activities stood at $863000.0 in 2022, then dropped by 12.05% to $759000.0 in 2023, then tumbled by 42.42% to $437000.0 in 2024, then sank by 49.2% to $222000.0 in 2025, then surged by 23198.2% to $51.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $51.7 million, $222000.0, and $50.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.